200 articles
What’s changing in cannabis law: our editors’ articles, and announcements straight from regulators, courts, governments and companies.
Company Calls for Consideration of New Regulatory Pathways and Cost Saving of Non-Hallucinogenic Neuroplastogens for Alcohol Use Disorder
Our psychedelic and mental health Investment Emyria (ASX: EMD) just opened its Sydney Empax clinic, with first patients already in treatment.
RN Collins has written a new series (3) of 18 articles for cannabis law report on 2026 Psychedelics & Legal Issues.
RN Collins has written a new series (3) of 18 articles for cannabis law report on 2026 Psychedelics & Legal Issues.
Mary-Elizabeth Gifford, Chief of Global Impact at Clearmind Medicine ( CMND ), spoke on patient access and shared insights from Clearmind’s clinical trial at Yale and Johns Hopkins
The first of two public hearings on proposed rules will begin tonight at 6:00pm (Pacific Time).
Adults looking for legal alcohol alternatives in 2026 can buy hemp-derived THC products, kratom, kava, kanna, and other modern botanicals online from HITT. But “alcohol alternative” is a shopping category, not a legal category.…
Psychedelic-Assisted Therapies Now Reaching Hundreds of Australians as Global Momentum Accelerates
Anyone who has spent time exploring the hemp and cannabinoid space eventually notices a pattern. Newcomers tend to focus on price or packaging, while experienced consumers ask deeper questions. They want to understand how a…
MAPS provided the first outside funding for the University of Miami ibogaine research program in the 1990s
RN Collins has written a new series (3) of 18 articles for cannabis law report on 2026 Psychedelics & Legal Issues.
The reported resubmission of the New Drug Application will initiate a new evaluation of the treatment’s safety and efficacy for potential FDA approval
, Aug. 5, 2026 /PRNewswire/ — Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer products in cannabis, today reported its financial and operating results…
WASHINGTON — The U.S. Department of Veterans Affairs today announced the launch of a new clinical trial to evaluate the effectiveness and safety of psilocybin to treat major depression in Veterans, including those with concurrent…
BOSTON, July 27, 2026 (GLOBE NEWSWIRE) — Rose Hill Life Sciences (“Rose Hill” or “the Company”), a clinical-stage biotechnology company advancing psychedelic therapeutics for neurological and psychiatric conditions, announced the…
WASHINGTON, D.C. — U.S. Senator John Fetterman (D-PA) joined his Senate Democratic colleagues in reintroducing the Cannabis Administration and Opportunity Act, comprehensive legislation that would end the harmful federal…
Leader Schumer, Sens. Booker, Wyden Reintroduce Legislation To End Federal Ban Of Marijuana
Header Image: https://www.pexels.com/photo/cannabis-buds-on-a-plate-18512088/
On Thursday, April 23, 2026, the acting U.S. Attorney General issued a final order and rule regarding the rescheduling of medical cannabis. The rule is titled “Schedules of Controlled Substances: Rescheduling of Food and Drug…
Yes as i read my way through this “article” it seemed to me a bit fishy, a thinly veiled press release for Exilby so i thought to myself let’s just ask google which law firm(s) represent Exilby
